Chemerin: A Novel Biomarker of Coronary Artery Disease

  • C Sahaya Jency Final Year Postgraduate Student, Department of Biochemistry, Vinayaka Missions Kirupananda Variyar Medical College, Salem, Tamil Nadu, India.
  • D Ponnudhali Professor & Head, Department of Biochemistry, Vinayaka Missions Kirupananda Variyar Medical College, Salem, Tamil Nadu, India.
Keywords: Chemerin, Coronary Artery Disease, Atherosclerosis, Adipokine


Introduction: Dysregulated secretion of adipokines causing adipose tissue dysfunction can contribute to the pathogenesis of obesity-linked complications like atherosclerosis. Chemerin, a newly discovered adipokine, secreted by visceral adipose tissue and liver, is involved in the regulation of glucose and lipid homeostasis. Elevated levels of chemerin in the blood have been associated with atherosclerosis and coronary artery disease.
Aim: To examine the chemerin levels in coronary artery disease (CAD) patients, to determine its association with CAD, and to find the correlation of chemerin with HsCRP and other lipid parameters.
Materials and Method: This is a cross-sectional study that included 100 participants divided into two groups namely, group I comprising CAD patients, and group II healthy individuals. Serum levels of chemerin were measured by ELISA. HsCRP were measured by immunoturbidimetry method. Atherogenic index of plasma (AIP), LDL and TC/ HDL ratios were calculated parameters.
Results: Chemerin levels were significantly increased in CAD patients (48.66 ± 12.7) (ng/ml) compared to healthy controls (32.92 ± 17) (ng/ml) (p = 0.04). AIP was significantly increased in CAD patients (6.92 ± 3.10) compared to healthy controls (3.27 ± 1.42) (p = 0.000). Chemerin had a good correlation with AIP (p = 0.001). Logistic regression analysis showed a significant association of chemerin with the occurrence of CAD (OR = 1.09, 95% CI, p = 0.004). ROC curve obtained with the area under the curve being 0.79.
Conclusion: Chemerin, a pro-inflammatory adipokine, could play an important role in atherosclerosis and can be used as a marker for the diagnosis of CAD patients.

How to cite this article:
Jency CS, Ponnudhali D. Chemerin: A Novel Biomarker of Coronary Artery Disease. Chettinad Health City Med J. 2023;12(1):24-31.



Ralapanawa U, Sivakanesan R. Epidemiology and the magnitude of coronary artery disease and acute coronary syndrome: a narrative review. J Epidemiol Glob Health. 2021 Jun;11(2):169-77. [PubMed] [Google Scholar]

Gupta R, Mohan I, Narula J. Trends in coronary heart disease epidemiology in India. Ann Glob Health. 2016 Mar-Apr;82(2):307-15. [PubMed] [Google Scholar]

Prabhakaran D, Jeemon P, Roy A. Cardiovascular diseases in India: current epidemiology and future directions. Circulation. 2016 Apr 19;133(16):1605-20. [PubMed] [Google Scholar]

Poznyak A, Grechko AV, Poggio P, Myasoedova VA, Alfieri V, Orekhov AN. The diabetes mellitus–atherosclerosis connection: the role of lipid and glucose metabolism and chronic inflammation. Int J Mol Sci. 2020 Mar 6;21(5):1835. [PubMed] [Google Scholar]

Malakar AK, Choudhury D, Halder B, Paul P, Uddin A, Chakraborty S. A review on coronary artery disease, its risk factors, and therapeutics. J Cell Physiol. 2019;234(10):16812-23. [PubMed] [Google Scholar]

Wang Z, Nakayama T. Inflammation, a link between obesity and cardiovascular disease. Mediators Inflamm. 2010 Oct;2010:535918. [PubMed] [Google Scholar]

Trujillo ME, Scherer PE. Adipose tissue-derived factors: impact on health and disease. Endocr Rev. 2006 Dec;27(7):762-78. [PubMed] [Google Scholar]

DeClercq V, Taylor C, Zahradka P. Adipose tissue: the link between obesity and cardiovascular disease. Cardiovasc Hematol Disord Drug Targets. 2008 Sep;8(3):228-37. [PubMed] [Google Scholar]

Nagpal S, Patel S, Jacobe H, DiSepio D, Ghosn C, Malhotra M, Teng M, Duvic M, Chandraratna RA. Tazarotene-induced gene 2 (TIG2), a novel retinoid-responsive gene in skin. J Invest Dermatol. 1997 Jul 1;109(1):91-5. [PubMed] [Google Scholar]

Goralski KB, McCarthy TC, Hanniman EA, Zabel BA, Butcher EC, Parlee SD, Muruganandan S, Sinal CJ. Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem. 2007 Sep 21;282(38):28175-88. [PubMed] [Google Scholar]

Bozaoglu K, Bolton K, McMillan J, Zimmet P, Jowett J, Collier G, Walder K, Segal D. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology. 2007 Oct;148(10):4687-94. [PubMed] [Google Scholar]

Takahashi M, Okimura Y, Iguchi G, Nishizawa H, Yamamoto M, Suda K, Kitazawa R, Fujimoto W, Takahashi K, Zolotaryov FN, Hong KS, Kiyonari H, Abe T, Kaji H, Kitazawa S, Kasuga M, Chihara K, Takahashi Y. Chemerin regulates β-cell function in mice. Sci Rep. 2011;1(1):123. [PubMed] [Google Scholar]

Yamamoto T, Qureshi AR, Anderstam B, Heimbürger O, Bárány P, Lindholm B, Stenvinkel P, Axelsson J. Clinical importance of an elevated circulating chemerin level in incident dialysis patients. Nephrol Dial Transplant. 2010 Dec 1;25(12):4017-23. [PubMed] [Google Scholar]

Weigert J, Obermeier F, Neumeier M, Wanninger J, Filarsky M, Bauer S, Aslanidis C, Rogler G, Ott C, Schäffler A, Schölmerich J, Buechler C. Circulating levels of chemerin and adiponectin are higher in ulcerative colitis and chemerin is elevated in Crohn’s disease. Inflamm Bowel Dis. 2010 Apr 1;16(4):630-7. [PubMed] [Google Scholar]

Bondue B, Wittamer V, Parmentier M. Chemerin and its receptors in leukocyte trafficking, inflammation and metabolism. Cytokine Growth Factor Rev. 2011 Oct 1;22(5-6):331-8. [PubMed] [Google Scholar]

Ernst MC, Sinal CJ. Chemerin: at the crossroads of inflammation and obesity. Trends Endocrinol Metab. 2010 Nov;21(11):660-7. [PubMed] [Google Scholar]

Dong B, Ji W, Zhang Y. Elevated serum chemerin levels are associated with the presence of coronary artery disease in patients with metabolic syndrome. Intern Med. 2011;50(10):1093-7. [PubMed] [Google Scholar]

Spiroglou SG, Kostopoulos CG, Varakis JN, Papadaki HH. Adipokines in periaortic and epicardial adipose tissue: differential expression and relation to atherosclerosis. J Atheroscler Thromb. 2010;17(2):115-30. [PubMed] [Google Scholar]

Elnoamany MF, Dawood AA, Aboelezz MA. Chemerin levels in patients with coronary artery disease. Menoufia Med J. 2020 Jan 1;33(1):288. [Google Scholar]

Wang B, Kou W, Ji S, Shen R, Ji H, Zhuang J, Zhao Y, Li B, Peng W, Yu X, Li H, Xu Y. Prognostic value of plasma adipokine chemerin in patients with coronary artery disease. Front Cardiovasc Med. 2022;9:968349. [PubMed] [Google Scholar]

Xiaotao L, Xiaoxia Z, Yue X, Liye W. Serum chemerin levels are associated with the presence and extent of coronary artery disease. Coron Artery Dis. 2012 Sep;23(6):412-6. [PubMed] [Google Scholar]

Wu Q, Chen Y, Chen S, Wu X, Nong W. Correlation between adiponectin, chemerin, vascular endothelial growth factor and epicardial fat volume in patients with coronary artery disease. Exp Ther Med. 2020 Feb;19(2):1095-102. [PubMed] [Google Scholar]

Aksan G, İnci S, Nar G, Soylu K, Gedikli Ö, Yüksel S, Özdemir M, Nar R, Meriç M, Şahin M. Association of serum chemerin levels with the severity of coronary artery disease in patients with metabolic syndrome. Int J Clin Exp Med. 2014;7(12):5461. [PubMed] [Google Scholar]

Er LK, Hsu LA, Juang JM, Chiang FT, Teng MS, Tzeng IS, Wu S, Lin JF, Ko YL. Circulating chemerin levels, but not the RARRES2 polymorphisms, predict the long-term outcome of angiographically confirmed coronary artery disease. Int J Mol Sci. 2019 Mar 7;20(5):1174. [PubMed] [Google Scholar]

Wittamer V, Franssen JD, Vulcano M, Mirjolet JF, Le Poul E, Migeotte I, Brézillon S, Tyldesley R, Blanpain C, Detheux M, Mantovani A, Sozzani S, Vassart G, Parmentier M, Communi D. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med. 2003 Oct 6;198(7):977-85. [PubMed] [Google Scholar]

Kaur J, Adya R, Tan BK, Chen J, Randeva HS. Identification of chemerin receptor (ChemR23) in human endothelial cells: chemerin-induced endothelial angiogenesis. Biochem Biophys Res Commun. 2010 Jan 22;391(4):1762-8. [PubMed] [Google Scholar]

Hansson GK, Robertson AK, Söderberg-Nauclér C. Inflammation and atherosclerosis. Annu Rev Pathol Mech Dis. 2006 Feb 28;1:297-329. [Google Scholar]

Sell H, Divoux A, Poitou C, Basdevant A, Bouillot JL, Bedossa P, Tordjman J, Eckel J, Clément K. Chemerin correlates with markers for fatty liver in morbidly obese patients and strongly decreases after weight loss induced by bariatric surgery. J Clin Endocrinol Metab. 2010;95(6):2892-6. [PubMed] [Google Scholar]

Kaur J, Mattu HS, Chatha K, Randeva HS. Chemerin in human cardiovascular disease. Vascul Pharmacol. 2018 Nov;110:1-6. [PubMed] [Google Scholar]

Bozaoglu K, Segal D, Shields KA, Cummings N, Curran JE, Comuzzie AG, Mahaney MC, Rainwater DL, VandeBerg JL, MacCluer JW, Collier G, Blangero J, Walder K, Jowett JB. Chemerin is associated with metabolic syndrome phenotypes in a Mexican-American population. J Clin Endocrinol Metab. 2009 Aug;94(8):3085-8. [PubMed] [Google Scholar]

Steinberg D. Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Nat Med. 2002 Nov;8(11):1211-7. [PubMed] [Google Scholar]

Marti A, Marcos A, Martinez JA. Obesity and immune function relationships. Obes Rev. 2001 May;2(2):131-40. [PubMed] [Google Scholar]

Ä°nci S, Aksan G, DoÄŸan P. Chemerin as an independent predictor of cardiovascular event risk. Ther Adv Endocrinol Metab. 2016 Apr;7(2):57-68. [PubMed] [Google Scholar]

Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011 Feb;11(2):85-97. [PubMed] [Google Scholar]

Landgraf K, Friebe D, Ullrich T, Kretsch J, Dittrich K, Herberth G, Adams V, Kiess W, Erbs S, Körner A. Chemerin as a mediator between obesity and vascular inflammation in children. J Clin Endocrinol Metab. 2012 Apr;97(4):E556-64. [PubMed] [Google Scholar]

Lehrke M, Becker A, Greif M, Stark R, Laubender RP, von Ziegler F, Lebherz C, Tittus J, Reiser M, Becker C, Göke B, Leber AW, Parhofer KG, Broedl UC. Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis. Eur J Endocrinol. 2009 Aug;161(2):339-44. [PubMed] [Google Scholar]

Kostopoulos CG, Spiroglou SG, Varakis JN, Apostolakis E, Papadaki HH. Chemerin and CMKLR1 expression in human arteries and periadventitial fat: a possible role for local chemerin in atherosclerosis? BMC Cardiovasc Disord. 2014 Dec;14(1):56. [PubMed] [Google Scholar]

Gao X, Mi S, Zhang F, Gong F, Lai Y, Gao F, Zhang X, Wang L, Tao H. Association of chemerin mRNA expression in human epicardial adipose tissue with coronary atherosclerosis. Cardiovasc Diabetol. 2011 Dec;10(1):87. [PubMed] [Google Scholar]